CD274 and glioma: Additionally, MLN4924 treatment increased the expression of PDL1 and its main transcriptional enhancer hypoxia-inducible factor 1A (HIF1A) in all glioma cell lines, which might cause potential resistance through evasion of immune surveillance checkpoints.